| 產品編號 | bs-2030R |
| 英文名稱 | Rabbit Anti-NMDAR1 antibody |
| 中文名稱 | 離子型谷氨酸受體1抗體 |
| 別 名 | NMDA-NR1; N-Methyl-d-Asprtate receptor 1; GRIN1; NMDA1; NR1; Glutamate [NMDA] receptor subunit zeta 1; Glutamate receptor ionotropic N methyl D aspartate 1; Grin 1; Grin1; N methyl D aspartate receptor channel; N-methyl-D-aspartate receptor; N-methyl-D-aspartate receptor subunit NR1; NMD-R1; NMDA 1; NMDA NR1; NMDA R1; NMDA receptor 1; NMDA1; NMDAR 1; NMDAR; NR 1; NMDZ1_HUMAN. |
 |
Specific References (2) | bs-2030R has been referenced in 2 publications.
[IF=2.666] X Zhou et al. Modulating NMDA receptors to treat MK-801-induced schizophrenic cognition deficit: effects of clozapine combining with PQQ treatment and possible mechanisms of action. BMC Psychiatry. 2020 Mar 6;20(1):106. WB ; rat.
[IF=1.947] Gao M et al. Activating the interleukin-6-Gp130-STAT3 pathway ameliorates ventricular electrical stability in myocardial infarction rats by modulating neurotransmitters in the paraventricular nucleus. BMC Cardiovasc Disord. 2020 Feb 5;20(1):60. IHC-P&WB ; Rat.
|
| 研究領域 | 細胞生物 神經生物學 信號轉導 細胞凋亡 細胞膜受體 細胞類型標志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Rat (predicted: Mouse,Pig,Cow,Chicken,Dog,Horse) |
| 產品應用 | IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1μg /test,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 103kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human NMDAR1: 101-200/938 <Extracellular> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
The protein encoded by this gene is a critical subunit of N-methyl-D-aspartate receptors, members of the glutamate receptor channel superfamily which are heteromeric protein complexes with multiple subunits arranged to form a ligand-gated ion channel. These subunits play a key role in the plasticity of synapses, which is believed to underlie memory and learning. Cell-specific factors are thought to control expression of different isoforms, possibly contributing to the functional diversity of the subunits. Alternatively spliced transcript variants have been described. [provided by RefSeq, Jul 2008] Function: NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors. Subunit: Forms heteromeric channel of a zeta subunit (GRIN1), a epsilon subunit (GRIN2A, GRIN2B, GRIN2C or GRIN2D) and a third subunit (GRIN3A or GRIN3B); disulfide-linked. Found in a complex with GRIN2A or GRIN2B, GRIN3A or GRIN3B and PPP2CB. Interacts with DLG4 and MPDZ. Interacts with LRFN1 and LRFN2. Interacts with MYZAP. Subcellular Location: Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane. Cell junction, synapse, postsynaptic cell membrane, postsynaptic density. Note=Enriched in post-synaptic plasma membrane and post-synaptic densities. Post-translational modifications: NMDA is probably regulated by C-terminal phosphorylation of an isoform of NR1 by PKC. Dephosphorylated on Ser-897 probably by protein phosphatase 2A (PPP2CB). Its phosphorylated state is influenced by the formation of the NMDAR-PPP2CB complex and the NMDAR channel activity. DISEASE: Defects in GRIN1 are the cause of mental retardation autosomal dominant type 8 (MRD8) [MIM:614254]. Mental retardation is characterized by significantly below average general intellectual functioning associated with impairments in adaptative behavior and manifested during the developmental period. Similarity: Belongs to the glutamate-gated ion channel (TC 1.A.10.1) family. NR1/GRIN1 subfamily. SWISS: Q05586 Gene ID: 2902 Database links: Entrez Gene: 2902 Human Entrez Gene: 14810 Mouse Omim: 138249 Human SwissProt: Q05586 Human SwissProt: P35438 Mouse Unigene: 558334 Human Unigene: 278672 Mouse Unigene: 9840 Rat 神經細胞標志物 (NMDAR1)N-甲基-D-天門冬氨酸受體(NMDAR)是興奮性氨基酸受體亞型之一，是由NMDAR1與不同的NMDAR2亞基組成的異聚體。 近年實驗研究發現，許多NMDAR拮抗藥均具有鎮痛活性，表明NMDAR在痛覺傳遞中具有重要作用，這為新型鎮痛藥的研究開發提供了新的作用靶點。 |
| 產品圖片 |
Paraformaldehyde-fixed, paraffin embedded (rat brain tissue); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (NMDAR1) Polyclonal Antibody, Unconjugated (bs-2030R) at 1:200 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Tissue/cell: rat spinal cord tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-NMDAR1 Polyclonal Antibody, Unconjugated(bs-2030R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Blank control (blue line): MCF7 (blue).
Primary Antibody (green line): Rabbit Anti-NMDAR1 antibody (bs-2030R)
Dilution: 1μg /10^6 cells;
Isotype Control Antibody (orange line): Rabbit IgG .
Secondary Antibody (white blue line): F(ab’)2 fragment goat anti-rabbit IgG-FITC
Dilution: 1μg /test.
Protocol
The cells were fixed with 2% paraformaldehyde for 10 min at room temperature.Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
